{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:08:01Z","timestamp":1793196481162,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Ornithine transcarbamylase deficiency (OTCD) is a rare hereditary metabolic disorder caused by mutations in the\n                      <jats:italic>OTC<\/jats:italic>\n                      gene. It is the most common urea cycle disorder (UCD), occurring in approximately one in 14,000 births worldwide. As an X-linked enzyme, OTC breaks down citrulline in mitochondria, and pathogenic variant can lead to dangerously high levels of ammonia (hyperammonemia) and glutamine (hyperglutaminemia) in the blood. Symptoms related to hyperammonemia include confusion, vomiting, coma, and cognitive impairments. Current treatments include ammonia scavengers and strict dietary management to limit protein intake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Given the rarity of OTCD and its varied clinical presentation, this study aimed to understand and characterize the burden of disease from the patient and caregiver perspective, develop preliminary symptoms and impacts conceptual frameworks based on the patient experience and caregiver observations, and contribute to the development of new clinical outcome assessments (COAs). The development of patient-centric conceptual frameworks is important to ensure that the unique experiences and needs of patients are accurately reflected in research and healthcare strategies, ultimately leading to more effective and personalized treatment approaches and disease measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The research involved a comprehensive literature review, interviews with key opinion leaders (KOLs), and concept elicitation interviews with patients and caregivers. These methods were employed to identify and validate relevant symptoms and impacts of OTCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most commonly reported symptom domains (i.e. neurocognitive, gastrointestinal, energy-related [fatigue\/tiredness], and physical symptoms) and impact domains (i.e. diet-related, emotional, physical, sleep, and social problems) reported by patients, caregivers, and KOLs were included in the preliminary conceptual frameworks. The research suggests that there is a high humanistic burden on patients that may be difficult to manage and negatively impacts quality of life for those living with OTCD. The findings of this study indicate that these frameworks encompass the concepts most important to patients and are aligned with Food and Drug Administration (FDA) guidance on human gene therapy for rare diseases which ensures that measures are scientifically valid, reliable, sensitive and responsive when used in clinical trials of novel treatments to document treatment benefit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This research highlights the need for COAs specific to OTCD based on the patient perspective in this disease population. This work helps to define the humanistic burden of disease and lays the foundation for identifying and developing robust COAs tailored to improve clinical assessments and patient care in OTCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00939-5","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:49:33Z","timestamp":1761122973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of patient-centric conceptual frameworks for symptoms and impacts of ornithine transcarbamylase deficiency (OTCD)"],"prefix":"10.1186","volume":"9","author":[{"given":"Christina","family":"Theodore-Oklota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"O\u2019Mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayna","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7864-4066","authenticated-orcid":false,"given":"Elizabeth","family":"Hribal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"939_CR1","first-page":"1779","volume":"15","author":"J Takanashi","year":"1994","unstructured":"Takanashi J, Barkovich JA, Cheng SF et al. (1994) Valproic acid-induced hyperammonemic encephalopathy: MR appearance. AJNR Am J Neuroradiol 15:1779\u20131781","journal-title":"AJNR Am J Neuroradiol"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1056\/NEJM199609193351204","volume":"335","author":"NE Maestri","year":"1996","unstructured":"Maestri NE, Brusilow SW, Clissold DB et al. (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335:855\u2013860","journal-title":"N Engl J Med"},{"key":"939_CR3","doi-asserted-by":"publisher","unstructured":"McBride KL, Miller G, Carter S et al. Developmental outcomes with early orthotopic liver transplantation for infants with neonatal-onset urea cycle defects and a female patient with late-onset ornithine transcarbamylase deficiency. Pediatrics 114. Epub ahead of print 2004. https:\/\/doi.org\/10.1542\/peds.2004-0198.","DOI":"10.1542\/peds.2004-0198"},{"key":"939_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jimd.12013","volume":"42","author":"C Buerger","year":"2019","unstructured":"Buerger C, Garbade SF, Dietrich Alber F et al. (2019) Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain-specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. J Inherit Metab Dis 42:243\u2013253","journal-title":"J Inherit Metab Dis"},{"key":"939_CR5","doi-asserted-by":"publisher","unstructured":"Ibrahim MS, Gold JI, Woodall A et al. (2023) Diagnostic and management issues in patients with late-onset ornithine transcarbamylase deficiency. Children 10. Epub ahead of print 1 August https:\/\/doi.org\/10.3390\/children10081368.","DOI":"10.3390\/children10081368"},{"key":"939_CR6","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1002\/acn3.51668","volume":"9","author":"S Scharre","year":"2022","unstructured":"Scharre S, Posset R, Garbade SF et al. (2022) Predicting the disease severity in male individuals with ornithine transcarbamylase deficiency. Ann Clin Transl Neurol 9:1715\u20131726","journal-title":"Ann Clin Transl Neurol"},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ymgme.2015.08.002","volume":"116","author":"SCS Nagamani","year":"2015","unstructured":"Nagamani SCS, Diaz GA, Rhead W et al. (2015) Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. Mol Genet Metab 116:29\u201334","journal-title":"Mol Genet Metab"},{"key":"939_CR8","unstructured":"Roth KS (2017) Ornithine Transcarbamylase (OTC) deficiency. Medscape. https:\/\/emedicine.medscape.com\/article\/950672-overview"},{"key":"939_CR9","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1542\/peds.2013-1324","volume":"133","author":"KR Bergmann","year":"2014","unstructured":"Bergmann KR, McCabe J, Smith TR et al. (2014) Late-onset ornithine transcarbamylase deficiency: treatment and outcome of hyperammonemic crisis. Pediatrics 133:e1072\u20136","journal-title":"Pediatrics"},{"key":"939_CR10","doi-asserted-by":"crossref","unstructured":"H\u00e4berle J, Boddaert N, Burlina A et al. (2012) Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 7:1\u201330","DOI":"10.1186\/1750-1172-7-32"},{"key":"939_CR11","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.3390\/biomedicines11082227","volume":"11","author":"B Seker Yilmaz","year":"2023","unstructured":"Seker Yilmaz B, Gissen P (2023) Genetic therapy approaches for ornithine transcarbamylase deficiency. Biomedicines 11:2227","journal-title":"Biomedicines"},{"key":"939_CR12","doi-asserted-by":"crossref","unstructured":"Murali CN, Barber JR, McCarter R et al. (2023) Health-related quality of life in a systematically assessed cohort of children and adults with urea cycle disorders. Mol Genet Metab 140:107696","DOI":"10.1016\/j.ymgme.2023.107696"},{"key":"939_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10545-015-9887-8","volume":"39","author":"D Jamiolkowski","year":"2016","unstructured":"Jamiolkowski D, K\u00f6lker S, Glahn EM et al. (2016) Behavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders. J Inherit Metab Dis 39:231\u2013241","journal-title":"J Inherit Metab Dis"},{"key":"939_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymgme.2019.07.009","volume":"128","author":"GM Enns","year":"2019","unstructured":"Enns GM, Porter MH, Francis-Sedlak M et al. (2019) Perspectives on urea cycle disorder management: results of a clinician survey. Mol Genet Metab 128:102\u2013108","journal-title":"Mol Genet Metab"},{"key":"939_CR15","doi-asserted-by":"crossref","unstructured":"Patrick DL, Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27:S217\u2013S232","DOI":"10.1097\/00005650-198903001-00018"},{"key":"939_CR16","unstructured":"US Food and Drug Administration (2018) Inborn errors of metabolism that use dietary management: considerations for optimizing and standardizing diet in clinical trials for drug product development guidance for industry DRAFT GUIDANCE 8"},{"key":"939_CR17","unstructured":"Kovacs S, Goldsmmith J, Shapiro EG et al. (2015) Assessing neurocognitive outcomes in inborn errors of metabolism 1\u201342"},{"key":"939_CR18","unstructured":"US Food and Drug Administration (2009) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims 301\u2013827"},{"key":"939_CR19","doi-asserted-by":"publisher","unstructured":"Mitani AA, Haneuse S (2020) Small data challenges of studying rare diseases. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1965","DOI":"10.1001\/jamanetworkopen.2020.1965"},{"key":"939_CR20","unstructured":"Research study | urea cycle disorders consortium. https:\/\/ucdc.rarediseasesnetwork.org\/research-study\/5101. (accessed 10 December 2024"},{"key":"939_CR21","doi-asserted-by":"publisher","unstructured":"Enns GM, Porter MH, Francis-Sedlak M et al (2019) Perspectives on urea cycle disorder management: results of a clinician survey. Mol Genet Metab 128. https:\/\/doi.org\/10.1016\/j.ymgme.2019.07.009","DOI":"10.1016\/j.ymgme.2019.07.009"},{"key":"939_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/jpepsy\/jsn017","volume":"33","author":"E Storch","year":"2008","unstructured":"Storch E, Keeley M, Merlo L et al. (2008) Psychosocial functioning in youth with glycogen storage disease type I. J Pediatr Psychol 33:728\u2013738","journal-title":"J Pediatr Psychol"},{"key":"939_CR23","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/life12111721","volume":"12","author":"B Seker Yilmaz","year":"2022","unstructured":"Seker Yilmaz B, Baruteau J, Arslan N et al. (2022) Three-country snapshot of ornithine transcarbamylase deficiency. Life 12:1721","journal-title":"Life"},{"key":"939_CR24","doi-asserted-by":"crossref","unstructured":"Domecq JP, Prutsky G, Elraiyah T et al. (2014) Patient engagement in research: a systematic review. BMC Health Serv Res 14:1\u20139","DOI":"10.1186\/1472-6963-14-89"},{"key":"939_CR25","doi-asserted-by":"crossref","unstructured":"Mayer M (2012) Seeking what matters: patients as research partners. Patient 5:71\u201374","DOI":"10.2165\/11632370-000000000-00000"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00939-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00939-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00939-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:38:08Z","timestamp":1781613488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00939-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00939-5","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study materials were initially submitted to WCG IRB on January 9, 2019 and received initial approval on January 29, 2019. Subsequent amendments were submitted over the course of the study to account for modifications to the study materials and approval of the final amendment submission was received on September 8, 2020. Prior to their participation, all study participants reviewed and signed the informed consent and HIPAA authorization form (ICF) and assent form (if applicable).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants reviewed and signed the informed consent and HIPAA authorization form (ICF), which included consent for publication, and assent form (if applicable). The ICF detailed precautions to protect personal health information and confirmed that if information about the study is published, participants\u2019 names will not be provided and the results will be reported at a group level.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ultragenyx authors were employees and stockholders of Ultragenyx.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}